Business Wire

Hillstone Networks Acknowledged as an XDR Leader in Frost Radar™ 2023 Report

Share

Hillstone Networks, a leading provider of cybersecurity solutions, has been named an innovation and growth leader in the 2023 Frost Radar™ Extended Detection and Response Report.

The Frost Radar™ 2023 Report is a market analysis conducted by Frost & Sullivan, evaluating industry participants based on their growth strategy, innovation, customer experience, and market share. The report aims to assist organizations in making informed decisions when selecting a reliable XDR solution provider.

“Our inclusion as a leader in the Frost Radar™ 2023 Report reaffirms our dedication to deliver cutting-edge solutions that effectively counter evolving digital threats,” states Tim Liu, CTO and Co-founder at Hillstone Networks. “Our solution integrates advanced threat detection, incident response, and forensic capabilities into a unified platform, empowering businesses to proactively safeguard their digital assets.”

According to Frost & Sullivan, XDR solutions have seen rapid expansion across geographies, industries, and companies of all sizes as it delivers the visibility, integration, analytics, flexibility, and automation that customers need in today’s complex IT environments. Frost states that XDR has three core promises: cross-layered detection and response, meaningful automation, and integration with the security stack.

"Hillstone Networks shows commitment to the Open XDR approach, as it is investing its significant R&D budget in increasing third-party integrations and providing software development kits (SDKs) to facilitate integration with its platform,” states Lucas Ferreyra, Industry Analyst at Frost & Sullivan. “Hillstone Networks has developed a compelling growth strategy, that involves leveraging the increasing relevance of managed security to allow MSSPs to use its XDR solution, broadening its reach while targeting high-growth sectors such as government, healthcare, education, and manufacturing. Such understanding of the market will allow Hillstone Networks to unlock further growth opportunities in the extremely competitive market of XDR.”

Hillstone’s commitment to continuous innovation and successful customer deployments contributes to its emergence as a frontrunner in the XDR domain, as well as delivering on the core promises of XDR:

  • Hillstone’s AI-powered threat detection and response capabilities can find and mitigate attacks before they have a chance to exploit the most vital asset in the enterprise – data. The Hillstone XDR solution uses advanced machine learning (ML) algorithms through unknown malware and abnormal detection, advanced threat correlation analytics, and automatic threat mitigation.
  • Hillstone XDR also includes automated orchestration and response. If a remediation strategy has been configured, once a threat is identified, Hillstone XDR will automatically execute the appropriate mitigation actions according to a predefined playbook.
  • It includes integration with a wide variety of data across the full spectrum of the network, from endpoints to cloud. This data can include NetFlow, Sysmon, Syslogs, metadata, threat information and third-party logs, all of which are then standardized, correlated, and analyzed to provide complete visibility and break down security information silos. It not only brings full security visibility with far fewer blind spots, but also improves detection accuracy by minimizing false positives.

Learn more about Hillstone XDR here.

About Hillstone Networks

Hillstone Networks is a leader in cybersecurity, delivering both depth and breadth of protection to companies of all sizes, from edge to cloud, and across any workload. Hillstone Networks’ Integrative Cyber Security approach brings coverage, control, and consolidation to more than 26,000 enterprises worldwide. www.hillstonenet.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Zeyao Hu
+1 4085086750
inquiry@hillstonenet.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye